Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 02 Mar 2023
Dietary nitrate in the form of beet juice reduces restenosis after percutaneous intervention in a randomized trial.
Read Full NewsA groundbreaking study reveals that combining ixekizumab and tirzepatide significantly improves outcomes for adults with psoriatic arthritis and obesity.
Coya Therapeutics reveals promising results for COYA 302, a potential treatment for frontotemporal dementia, showing cognitive stability and Treg enhancement.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the International Stroke Conference (ISC)!
Here's some of what is coming soon to NeurologyLive® this week.
FDA Clears LEADOPTIK's LIA System for Higher-Accuracy Lung Biopsy
1.
Researchers use AI to monitor side effects of chemotherapy and support families dealing with pediatric cancer.
2.
Innovative oncology therapeutics are being created in collaboration between Moderna and Immatics.
3.
Pivotal Studies in Double-Expressor DLBCL Yield Divergent Results
4.
Journal Club: A well-accepted and safe method for soft tissue sarcoma biopsy.
5.
Gene Therapy for Hemophilia B Significantly Outperforms Factor IX Prophylaxis
1.
Radiation in Oncology: Advances, Applications, and Accessibility
2.
The Danger of Methemoglobinemia and How to Prevent It
3.
Unlocking the Mysteries of Synovial Sarcoma: A New Hope for Treatment
4.
Epigenetics and Resistance: Mechanisms in Histone Methylation-Targeted Therapies
5.
Exploring the Effects of Radiation Therapy on Cystitis: A Journey to Better Health
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Current Scenario of Cancer- Final Discussion on the Importance of Genomic Testing & Advancement in Diagnosis and Treatment
2.
Efficient Management of First line ALK-rearranged NSCLC
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part III
4.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part V
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part III
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge